Compare Salesforce Inc (CRM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs TransMedics Group Inc — how do they compare? Salesforce Inc trades at $166.78 (market cap $137.23B), while TransMedics Group Inc trades at $75.56 (market cap $2.58B). The key difference: Salesforce Inc is far larger — about 53.2× TransMedics Group Inc's market cap, and Salesforce Inc pays a 1.05% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| CRM | TMDX | |
|---|---|---|
Market Cap | $137.23B | $2.58B |
Sector | Technology | Technology |
52-Week High | $270.25 | $150.42 |
52-Week Low | $150.12 | $61.99 |
Enterprise Value | $167.28B | $2.98B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $167.70, down 2.06% amid broader software sector weakness. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs $3.13 expected) and robust profitability (77.6% gross margin). Technical indicators are neutral with support at $165 and resistance at $171. Recent AI-driven growth initiatives, including Agentforce reaching $2.9B ARR, position the company for continued expansion despite current market pressures.
CRM presents a compelling long-term opportunity with 76.8% analyst buy ratings and a $235.90 consensus target (40% upside). Risks include sector volatility from AI competition and macroeconomic headwinds, but strong cash flow generation ($13.1B operating cash flow in 2025) and market leadership support the bullish case for patient investors.
TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.
The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
